United States · Venture startup

Who invested in MediCool Technologies

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

Undisclosedraised across 1 round since 2023, from 1 source

Latest round
VentureMay 2023
Investors
2
See who backed them

The rounds

  1. May 2023
    VentureAmount undisclosed

    Source recorded

Founders and team

From MediCool Technologies's own website and the SEC filings it signed: 9 on the team.

  • Jeff RynbrandtChief Executive Officer
  • Peter von AltChief Financial Officer
  • Dr. Paul FriedmanChief Technology Officer
  • Dr. Sam AsirvathamChief Medical Officer
  • Alan WitzSecretary & General Counsel
  • Mellanie HillsBoard of Directors
  • Allan WitzExecutive Officer, Directori
  • Paul WilliamsDirector
  • Rich SandersExecutive Chairman

Everyone who backed them

Michigan RiseVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about MediCool Technologies

Who invested in MediCool Technologies?

MediCool Technologies's investors include National Science Foundation and Michigan Rise.

How much has MediCool Technologies raised?

MediCool Technologies has raised 1 round since 2023, none with a disclosed amount.

When did MediCool Technologies last raise?

MediCool Technologies's most recent round was a Venture in May 2023.

Who backed MediCool Technologies first?

MediCool Technologies's first round on record, in May 2023, was backed by National Science Foundation and Michigan Rise.

What stage is MediCool Technologies at?

MediCool Technologies's latest named round is a Venture, in May 2023.

Where is MediCool Technologies based?

MediCool Technologies is based in the United States.

Companies like MediCool Technologies

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.